From the nadir of tumor size, a triple combination of BRAFi, MEKi, and OPN-9652 extended median survival compared to BRAFi + MEKi alone from 21.5 days to 27 days (Supplementary Fig. 9C, D). This evidence concerns the gene SPP1 and neoplasm.